Novavax reported $861.77M in Operating Expenses for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Adma Biologics ADMA:US USD 18.97M 24.11M
Agenus AGEN:US USD 64.42M 1.07M
AstraZeneca AZN:LN USD 9.74B 495M
Astrazeneca AZN:US USD 9.74B 495M
Biocryst Pharmaceuticals BCRX:US USD 93.27M 6.98M
Dynavax Technologies DVAX:US USD 106.34M 21.9M
Genocea Biosciences GNCA:US USD 16.04M 2.63M
Geron GERN:US USD 40.24M 12.2M
GlaxoSmithKline GSK:LN GBP 6.64B 790M
Mannkind MNKD:US USD 42.43M 3.09M
Merk MRK:US USD 10.97B 1.31B
Minerva Neurosciences NERV:US USD 5.21M 1.76M
Moderna Inc MRNA:US USD 2.2B 104M
Novartis NVS:US USD 10.67B 183M
Novavax NVAX:US USD 861.77M 192.88M
Pain Therapeutics PTIE:US USD 21.34M 1.43M
Peregrine Pharmaceuticals PPHM:US USD 33.96M 3.8M
Pfizer PFE:US USD 13.23B 2.41B
Sarepta Therapeutics SRPT:US USD 487.06M 42.45M
Tg Therapeutics TGTX:US USD 35.06M 4.48M